Palovarotene
- Generic Name
- Palovarotene
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30N2O2
- CAS Number
- 410528-02-8
- Unique Ingredient Identifier
- 28K6I5M16G
- Background
Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive heterotopic ossification, a process wherein connective tissues (e.g. skeletal muscle, ligaments, tendon...
- Indication
Palovarotene is indicated in Canada to reduce the formation of heterotopic ossification in adults and children (≥8 years old for females and ≥10 years old for males) with Fibrodysplasia Ossificans Progressiva (FOP) by Health Canada and FDA.
- Associated Conditions
- Heterotopic Ossification (HO)
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath